BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Seitz JF, Perrier H, Giovannini M, Capodano G, Bernardini D, Bardou VJ. 5-Fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma. J Chemother. 1998;10:258-265. [PMID: 9669654 DOI: 10.1179/joc.1998.10.3.258] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Hartmann J T, Oechsle K, Quietzsch D, Wein A, Hofheinz RD, Honecker F, Nehls O, Köhne CH, Käfer G, Kanz L. Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study. Br J Cancer. 2003;89:2051-2056. [PMID: 14647137 DOI: 10.1038/sj.bjc.6601412] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
2 Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol. 2005;56:10-14. [PMID: 15782313 DOI: 10.1007/s00280-004-0963-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
3 Bouche O, Conroy T, Michel P, Penna C, Tournigand C. Metastatic colorectal cancer. Gastroentérologie Clinique et Biologique 2006;30:30-42. [DOI: 10.1016/s0399-8320(06)73587-4] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
4 Deng YC, Zhen YS, Zheng S, Xue YC. Activity of boanmycin against colorectal cancer. World J Gastroenterol 2001; 7(1): 93-97 [PMID: 11819740 DOI: 10.3748/wjg.v7.i1.93] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
5 Bradner W. Mitomycin C: a clinical update. Cancer Treatment Reviews 2001;27:35-50. [DOI: 10.1053/ctrv.2000.0202] [Cited by in Crossref: 206] [Cited by in F6Publishing: 175] [Article Influence: 10.3] [Reference Citation Analysis]
6 Grumett SA, Archer VR, Midgley R, Mulholland P, Nicum S, Blewitt L, Kerr DJ. The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy. Ann Oncol 2001;12:575. [PMID: 11398896 DOI: 10.1023/a:1011106917263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Carlomagno C, Lauria R, De Laurentiis M, Arpino G, Massarelli E, Ferrara C, Milano A, Vernaglia Lombardi A, Costanzo R, Catalano G, Bianco A, De Placido S. Second-Line Chemotherapy with a Hybrid-Alternating Regimen of Bolus 5FU Modulated by Methotrexate and Infusional 5FU Modulated by Folinic Acid in Patients with Metastatic Colorectal Cancer Pretreated with 5FU. Oncology 2002;63:219-25. [DOI: 10.1159/000065468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Rougier P. Palliative and adjuvant chemotherapy in colorectal cancer. European Journal of Cancer 2001;37:189-202. [DOI: 10.1016/s0959-8049(01)80020-4] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
9 Dimou A, Syrigos KN, Saif MW. Is there a role for mitomycin C in metastatic colorectal cancer? Expert Opinion on Investigational Drugs 2010;19:723-35. [DOI: 10.1517/13543784.2010.485191] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
10 Kamphuis JAM, Linschoten M, Cramer MJ, Gort EH, van Rhenen A, Asselbergs FW, Doevendans PA, Teske AJ. Cancer Therapy-Related Cardiac Dysfunction of Nonanthracycline Chemotherapeutics: What Is the Evidence? JACC CardioOncol 2019;1:280-90. [PMID: 34396190 DOI: 10.1016/j.jaccao.2019.09.007] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Goyle S, Maraveyas A. Chemotherapy for colorectal cancer. Dig Surg 2005;22:401-14. [PMID: 16479107 DOI: 10.1159/000091441] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
12 Lawes D, Taylor I. Chemotherapy for colorectal cancer--an overview of current management for surgeons. Eur J Surg Oncol 2005;31:932-41. [PMID: 15979268 DOI: 10.1016/j.ejso.2005.03.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Ghiringhelli F, Guiu B, Chauffert B, Ladoire S. Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: A pilot study. World J Gastroenterol 2009; 15(34): 4278-4283 [PMID: 19750570 DOI: 10.3748/wjg.15.4278] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
14 Müller H, Nakchbandi W, Chatzissavvidis I, Valek V. Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases. Eur J Surg Oncol 2001;27:652-61. [PMID: 11669594 DOI: 10.1053/ejso.2001.1193] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]